Enzolytics has made impressive progress in its mission to create Monoclonal Antibodies to treat animals, filing a patent application to protect its discovery of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus. Using its advanced Artificial Intelligence technology, the Company identified more than 26 immutable epitopes on the virus – now claimed in the patent.
These epitopes can be used to develop monoclonal antibodies, vaccines, and diagnostic tests for detecting the virus in cats. The patent is held by the Company’s wholly owned subsidiary Biogenysis, Inc., which manages this technology field on behalf of Enzolytics.
The Company’s focus is on producing monoclonal antibodies that could treat a variety of human viruses, such as COVID-19, HIV, Influenza A and B, and Smallpox. But that’s not all! Our research has also extended to analyzing epitopes of animal viruses, such as Feline Leukemia Virus, Equine Infectious Anemia Virus, Koala Retrovirus, and Elephant Endotheliotropic Herpes Virus.
We have identified the conserved, immutable sites on these viruses, and plan to use this knowledge to produce monoclonal antibodies. Our findings will be protected by U.S. and foreign patent applications.
Targeting the conserved sites discovered by Enzolytics is an effective way to create a therapeutic that will remain effective against viral mutations. By targeting these immutable sites, the potential for a therapeutic or vaccine to become ineffective due to a mutated virus is eliminated. By taking this approach, we can ensure that our therapeutics and vaccines remain effective against even the most variant forms of the virus.
Cat Feline Leukemia (FeLV) is a life-altering virus that has been devastating the cat population both in the United States and around the world. Despite the fact that there is currently no cure, it is estimated that one in four households in America alone own at least one cat, making the population of cats in the US alone 45 million strong. This means that a significant percentage of the cat population is vulnerable to this dangerous virus, leaving millions of cats suffering from the virus with no cure in sight.
The Company is taking this animal virus by the horns, introducing groundbreaking monoclonal antibody therapies that will reduce treatment time for animals dramatically. This innovation has already sparked interest among animal health providers, who are eager to bring this revolutionary therapy to market. With this cutting-edge technology, the Company is revolutionizing the way we tackle animal viruses.
At our lab located at the Texas A&M University Institute for Preclinical Studies, we produce fully species-specific monoclonal antibodies that target the most conserved, immutable sites on viruses.
Our proprietary methodology ensures that our monoclonal antibodies are not rendered ineffective by virus mutation. This cutting-edge process gives our products an edge over traditional methods, allowing us to offer the highest quality antibodies available.
Using Artificial Intelligence (AI), Enzolytics has developed a proprietary platform that can identify conserved, immutable epitopes on any virus. By analyzing the sequences of virus isolates, the AI platform is able to pinpoint target sites that are shared across all isolates.
This information is then used in the Company’s production process to create monoclonal antibodies that are tailored to target these conserved sites – a process that is currently the subject of the Company’s pending international patent applications.
Enzolytics is using cutting-edge technology to generate 3D models of conserved virus targets, and then analyze them for linearity, antibody accessibility, and neutralizability. With this process, they are able to create multiple broadly neutralizing antibodies targeting conserved, immutable epitopes on the targeted virus. This groundbreaking work is paving the way for the development of more effective treatments for a wide range of viruses.
Enzolytics is revolutionizing the production of monoclonal antibodies with its unique and innovative methodology. For the development of a monoclonal antibody to treat an animal virus, the Company obtains immune-B cells from animals that have recovered from the virus, allowing them to maintain the original antibody affinity and specificity while minimizing the chances of immunogenicity. This remarkable process sets Enzolytics apart from other biotech companies.
Enzolytics’ Focus on Intellectual Property (IP)
Enzolytics is committed to pushing the boundaries of science and clinical products, and is taking steps to ensure it maintains a competitive edge through its expanding Intellectual Property portfolio.
According to Gaurav Chandra, MD and Company COO, “Intellectual property protection is essential to fostering innovation and our strategy is to gain a foothold in the market through an aggressive patent strategy.”
Charles Cotropia, the Company CEO, praised the patent system as an ideal way for small biotech companies to protect their intellectual property for up to two decades, even before or without bringing a therapeutic to market.
By filing a patent application, the company is able to lay claim to the subject matter described in the application. As Mr. Cotropia puts it, “We are taking every opportunity to cover the waterfront on all the viruses we are analyzing.”
Our patent portfolio is set to cover a wide range of viruses, including HIV, COVID-19, HIV-2, Influenza A and B, H1N1 influenza, Respiratory syncytial virus (RSV), Small-Pox, Ebola Virus, Tetanus, Diphtheria, HTLV-1/2, Rabies, Herpes zoster, Varicella zoster, Anthrax, Mason-Pfizer monkey virus (MPMV) and Visna virus (VISNA).
Using our AI platform, we have identified conserved epitopes in all of these viruses which will be subjected to international patent protection. This protection will cover the epitopes/antigens for use in producing therapies, vaccines, or related prophylactic/therapeutic methods, as well as for diagnostics. We are confident that our extensive patent portfolio will help us make great strides in neutralizing these viruses effectively.